[topsearch__bar__shortcode]

July 2024

Lipella Pharmaceuticals Inc. Surges with Phase 2a Initiation

Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) has been garnering attention recently. On Friday, the stock saw a modest 2.3% increase during regular trading hours. However, by early Monday premarket hours, the stock soared an additional 65%, moving from $0.39 to $0.69. This dramatic rise has sparked significant interest among investors, with many bullish on the stock […]

Lipella Pharmaceuticals Inc. Surges with Phase 2a Initiation Read More »

Longeveron Inc. Sees Remarkable Surge on Pipeline Update

Longeveron Inc. (NASDAQ: LGVN) has been a standout performer recently. After climbing 13% during Friday’s regular trading session, the stock continued its impressive trajectory, soaring an additional 43% in early premarket trading on Monday. This surge moved the stock from $3.04 to $4.91, with many bulls anticipating it could surpass the $5 mark during Monday’s

Longeveron Inc. Sees Remarkable Surge on Pipeline Update Read More »

vTv Therapeutics Faces Major Plunge Following FDA Hold

vTv Therapeutics Inc. (NASDAQ: VTVT) experienced a tumultuous Friday, with its stock plummeting 38% in afterhours trading. This sharp decline follows an already lackluster regular trading session, where the stock saw a modest increase of 0.52%. The drastic drop has left shareholders reeling and has drawn significant attention to the company’s recent developments. Unexpected Volume

vTv Therapeutics Faces Major Plunge Following FDA Hold Read More »

Clean Energy Stocks

Ambipar Emergency Surges in Afterhours without News

Ambipar Emergency Response (NYSE: AMBI) has been gaining significant attention lately. On Friday, the stock saw an impressive 30% increase during regular trading hours. However, the excitement did not end there. Following the closing bell, Ambipar continued its upward trajectory in afterhours trading, surging an additional 24%. This remarkable movement propelled the stock from $3.58

Ambipar Emergency Surges in Afterhours without News Read More »

ENSV Stock

DDC Enterprise Limited Sees Spontaneous Afterhours Surge

DDC Enterprise Limited (NYSE: DDC) has garnered significant attention following a remarkable performance on Friday. The stock posted a 6.2% gain during the regular trading session, but the real excitement came after the market closed. In a dramatic afterhours move, DDC’s stock skyrocketed by an additional 30%, propelling its price from $0.56 to $0.80. This

DDC Enterprise Limited Sees Spontaneous Afterhours Surge Read More »

Understanding the biotech industry

Cognition Therapeutics Soars with Alzheimer’s Trial Progress

Cognition Therapeutics, Inc. (NASDAQ: CGTX) made headlines with a remarkable 13% gain during Friday’s regular trading session. However, the stock’s performance was far from over. As the trading bell closed and the afterhours session began, CGTX surged an additional 53%, catapulting from $2.10 to $3.63. This unprecedented afterhours rally saw approximately 4 million shares exchanging

Cognition Therapeutics Soars with Alzheimer’s Trial Progress Read More »

Carbon Revolution (CREV) Shares Soar Following New Supply Order

After announcing a significant new supply order, shares of Carbon Revolution Public Limited Company (NASDAQ: CREV) have experienced a remarkable surge on the US stock charts. As of the latest current-market check, CREV stock had risen by 37.12%, reaching $8.46. Carbon Revolution Collaborating with General Motors The news that Carbon Revolution (CREV) would provide the

Carbon Revolution (CREV) Shares Soar Following New Supply Order Read More »

Windtree (WINT) Sees Major Market Gains After Istaroxime Trial Progress

Windtree Therapeutics, Inc. (NASDAQ: WINT) has experienced a significant rise in the value of its shares following the most recent report on its clinical studies. The latest current-market check showed that WINT shares have increased by 104.55% to $6.75. Windtree Advancing The Clinical and Business Development of Istaroxime Significant advancements have been made in the

Windtree (WINT) Sees Major Market Gains After Istaroxime Trial Progress Read More »